Tag: progressive MS

Advances in treatment and research.

Recent advances and promising researches

MSIF Du Pré Grants enable multiple sclerosis researchers and clinicians to undertake short placements in established MS research centres and clinics

Catch up on advances in treatment and research.

The first adaptive clinical trial for Australians living with MS

Advances in treatment and research.

Research advances that could lead to breakthrough treatments in progressive MS

International Progressive MS Alliance invests €3 million in drug discovery project to develop therapies to stop MS progression.

Answering questions and exploring advances in research

The International Progressive MS Alliance works to speed up the development of treatment for progressive MS

Catch up with the latest webcast on unraveling the mystery of progression and identifying new targets for treatments

Learn about important, new research initiatives that will fuel the development of breakthrough treatments for progressive MS.  

Thousands of scientists are undertaking research into all aspects of MS, furthering our understanding of the disease and how to prevent, treat and manage it.

Leaders of the International Progressive MS Alliance have published a paper proposing a global research strategy to prioritise and coordinate the efforts needed to find more and better treatments, and improve quality of life of people living with progressive MS.

MSIF is proud to announce the recipients of the 2021 McDonald Fellowships and Du Pré Grants, from Argentina, Brazil, Egypt, Iran, and Tunisia

Find out about the lives of seven people affected by progressive MS.

Professor Thompson wins the 2021 lifetime achievement award for outstanding research into the understanding and treatment of MS

In time for World MS Day, €1,425,000 has been awarded to help identify new therapeutic targets in progressive MS

Watch the International Progressive MS Alliance webcast

Research and clinical trials are taking place around the world, trying to find and improve treatments for MS

A first-of-its-kind global research network funded by the International Progressive MS Alliance aims to develop new, effective treatments for progressive MS.

Global webcast on 4 March

This paper was first published in Nature January 2021

MSIF is proud to announce the recipients of the 2020 McDonald Fellowships and Du Pré Grants, from Iran, Zambia, Brazil, Turkey, and Argentina

Register for the Progressive MS Alliance's Facebook Live event

Genetic screening of people with primary progressive MS has shown that four rare genetic changes, which are known to cause other neurological diseases, may play a role in primary progressive MS.

The use of neurofilament light chain (NfL) as a biomarker could revolutionise clinical trials in progressive MS.

Join the discussion about research breakthroughs that could accelerate new treatments for people with progressive MS

New research funded by the International Progressive MS Alliance looks at ways that nerve fibres protect themselves from damage.

Watch the International Progressive MS Alliance webcast here

An International Progressive MS Alliance global webcast

Cord lesion load and spinal cord atrophy may contribute to disability in people with progressive MS

An important milestone for people with secondary progressive MS in Europe

Register for the Progressive MS Alliance's Facebook Live event on symptom management and well-being in progressive MS

Progressive MS Awards

The International Progressive MS Alliance is growing!

The results of the MS-SMART trial, an innovative trial testing multiple drugs at the same time, have ruled out three repurposed drugs for the treatment of progressive MS.

A phase II clinical trial has shown ibudilast, a repurposed asthma medication, can slow down the rate of brain tissue loss in progressive MS by almost half compared to a placebo treatment.

Researchers, clinicians and people living with MS, from around the world converged on the city of Toronto in Canada for the 3rd Congress of the International Progressive MS Alliance.

How the biological processes cause progression in different types of MS.

A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.

Screening of almost 250 medications has identified clomipramine as a possible treatment for progressive MS.

The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).

The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS

Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US

Neurobiology and immunology are key areas of MS research

Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS

Video from Caroline Sincock who recently joined the International Progressive MS Alliance

Our highlights from the world’s largest scientific conference on multiple sclerosis

Challenges and next steps considered

Full text of our 2014 webinar with experts on progressive MS

A recent study has failed to show any benefit for Rituximab in people with secondary progressive MS

A new trial has failed to show Fingolimod has any effect of in primary-progressive MS

Long-term follow-up studies could help determine predictive factors for long-term clinical outcomes

Chemical in the brain involved in signaling may play a role in progressive MS

The Charcot Award recognises a lifetime of achievement in MS research

Collaborative Network Planning Awards Granted as part of €22 million global effort to End Progressive MS

On 6 October, 650 people affected by MS gathered in Barcelona for the ‘Living with MS Day’ event

The results from a phase III clinical trial of Ocrelizumab in primary progressive MS are announced at ECTRIMS

Recovery from early relapses can potentially delay or prevent onset of progressive MS

Researchers in Canada have investigated the natural history of 500 people with primary progressive MS

There is a need to identify direct biomarkers of inflammation within the central nervous system

Researchers are looking for new biomarkers of disease, which could also recognise progression of MS in a reasonable time

Study suggests that early spinal neurodegeneration may underlie clinical impairment

Three people needed to help shape the work of the Alliance

Study supports a link between the development of grey matter disease and a progressive MS phenotype

Neurofilaments are a good way to monitor nerve damage and treatments in progressive MS

Researchers found a lower risk of disability progression at the 10-year follow-up in the RRMS group compared with historical cohorts

The Alliance has been joined by four MS International Federation member organisations

Patients with secondary progressive MS who have ongoing relapses may benefit from continuing immunomodulatory therapies after onset of progressive MS

The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms

The Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries

MS comes in several forms, including clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS and primary progressive MS.